VIRX - AstraZeneca's updated data to address integrity issue; Vertex moves to focus list at Citi in today's analyst action

Updated interim data provided by AstraZeneca (AZN) yesterday from its late-stage COVID-19 vaccine trial in the U.S., should address the data integrity issue, UBS wrote in a note. AstraZeneca ADRs are trading marginally up in before hours.The Analysts led by Michael Leuchten with a buy rating on the stock say the 3% difference with the preliminary assessment which indicated ~79% efficacy in preventing symptomatic COVID-19 “is really nothing to be concerned about.”Vertex Pharmaceuticals (VRTX) was added to Focus List at Citi with the price target of $325.00 per share indicating a premium of ~53.6%.With a buy rating, the analyst Mohit Bansal highlights the current valuation and low investor sentiment despite a slew of potential 2021 catalysts which includes the data read from VX-864 Phase 2 proof-of-concept study in Alpha-1 Antitrypsin (“AAT”) deficiency expected in H1 2021.SPDR Biotech ETF (XBI) has just recorded two back-to-back one-day declines of more than ~5% for the

For further details see:

AstraZeneca’s updated data to address integrity issue; Vertex moves to focus list at Citi in today’s analyst action